Development and validation of artificial intelligence-based analysis software to support screening system of cervical intraepithelial neoplasia
Yung‐Taek Ouh, Hye Yeon Moon, Kyung‐Jin Min, Tae Jin Kim, Woong Ju, Sang Wun Kim, Jeon Sub, Soo‐Nyung Kim, Kwang Gi Kim, Jae Kwan Lee · 2024
The 8 th Biennial Meeting of ASGO 2023 protein 1 (PD-1) and/or anti-cytotoxic T-lymphocyte associated protein (CTLA)-4, and their proliferation was assessed.Immunohistochemical staining for ARID1A and L1CAM was performed using paraffin-embedded tumor tissue block.Results: Tumor-reactive CD39+CD103+CD8 T cells were enriched in TILs and exhibited higher expression of immune checkpoint receptors, including PD-1, CTLA-4, and 4-1BB, compared to peripheral T cells.In addition, tumor-reactive 4-1BB+ regulatory T cells (Tregs) were enriched in TILs and showed highly suppressive immune-phenotypes.Among 31 patients, 17 (54.8%)had ARID1A loss and 6 (19.4%) had L1CAM over-expression.ARID1A loss group had significantly low TCF-1+PD-1+CD8 TILs, and L1CAM over-expression group had significantly low tumorreactive 4-1BB+CD8 TILs.When evaluating the proliferative capacity of CD8 TILs after ex vivo stimulation, anti-PD-1-induced reinvigoration of CD8 TILs were correlated with exhausted status of CD8 TILs and infiltration of Tregs.When anti-CTLA-4 was used in combination with anti-PD-1, an additional increase in CD8 TIL proliferation was observed in patients who responded well to anti-PD-1 in the ex vivo assay, and the response were correlated with ARID1A expression.In survival analysis, the patients with L1CAM expression showed shorter progression-free survival than those without L1CAM expression (p=0.0205;hazard ratio=2.68). Conclusion:In the current study, we comprehensively explored the immune properties of TILs in OCCC and found that the exhausted status of CD8 TILs, infiltration of Tregs, and ARID1A expression correlated with response to ICBs.Further studies are needed to elucidate the reasons for poor PFS in patients with L1CAM expression and to find predictive immune biomarkers in OCCC for ICB treatment.